Overview
- The story moved from mice and cell studies into the clinic when the U.S. Food and Drug Administration cleared Life Biosciences’ ER 100 to begin human trials in January 2026 as a test of epigenetic reprogramming for some causes of blindness.
- David Sinclair’s lab says its OSK reprogramming can roll back epigenetic age in human cells by as much as 75% in vitro and restored vision in aged mice, and the team says omitting the Myc gene may reduce cancer risk during reprogramming.
- Eric Verdin frames aging as the primary risk factor for many chronic diseases and points to targets such as mitochondria, chronic inflammation, and the microbiome as ways to slow biological aging and protect multiple organs at once.
- Both researchers and reporters stress that clinical proof is still limited: ER 100 trials are early-stage, long-term safety and efficacy—including cancer risk and lasting benefits—remain unproven, and scientific consensus has not been reached.
- Beyond experimental drugs, experts recommend proven lifestyle measures such as exercise, sleep, and dietary practices to lower aging risk now, and they warn successful therapies would shift health care toward prevention while raising ethical and regulatory questions.